A Decade of Experience Using mTor Inhibitors in Liver Transplantation
Some studies suggest that Sirolimus (SRL) is associated with an increased risk of death in liver transplant recipients compared to treatment with calcineurin inhibitors (CNIs). We compared patients who received SRL or CNI in the first year after liver transplant. Our database included 688 patients...
Saved in:
Main Authors: | Jeffrey Campsen, Michael A. Zimmerman, Susan Mandell, Maria Kaplan, Igal Kam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2011/913094 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
by: Goran B. Klintmalm, et al.
Published: (2014-01-01) -
Combined Piggyback Technique and Cavoportal Hemitransposition for Liver Transplant
by: Jeffrey Campsen, et al.
Published: (2010-01-01) -
Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
by: Gianluigi Zaza, et al.
Published: (2013-01-01) -
Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment
by: Jiarui Lv, et al.
Published: (2025-01-01) -
Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma
by: J. Martin-Liberal, et al.
Published: (2014-01-01)